US7022683B1
(en)
*
|
1998-05-13 |
2006-04-04 |
Carrington Laboratories, Inc. |
Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
|
US20030206958A1
(en)
*
|
2000-12-22 |
2003-11-06 |
Cattaneo Maurizio V. |
Chitosan biopolymer for the topical delivery of active agents
|
US7494669B2
(en)
*
|
2001-02-28 |
2009-02-24 |
Carrington Laboratories, Inc. |
Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
|
US6777000B2
(en)
*
|
2001-02-28 |
2004-08-17 |
Carrington Laboratories, Inc. |
In-situ gel formation of pectin
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
BR0210628A
(pt)
*
|
2001-06-29 |
2004-08-10 |
Becton Dickinson Co |
Liberação intradérmica de vacinas e agentes terapêuticos genéticos via microcânula
|
KR20040073438A
(ko)
*
|
2001-11-19 |
2004-08-19 |
벡톤 디킨슨 앤드 컴퍼니 |
입자 형태의 약제학적 조성물
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
SI1549338T1
(sl)
|
2002-10-11 |
2011-04-29 |
Novartis Vaccines & Diagnostic |
Polipeptidna cepiva za ĺ iroko zaĺ äśito pred hipervirulentnimi miningokoknimi rodovi
|
WO2004046177A2
(en)
|
2002-11-15 |
2004-06-03 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
PT2191844E
(pt)
|
2003-01-30 |
2014-06-04 |
Novartis Ag |
Vacinas injetáveis contra múltiplos serogrupos meningocócicos
|
EP1594536B1
(de)
*
|
2003-01-30 |
2009-03-25 |
Novartis Vaccines and Diagnostics, Inc. |
Adjuvante influenza-vakzine
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
EP1618127B1
(de)
|
2003-04-10 |
2014-12-10 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenische Zusammensetzung einer Spikeprotein des SARS Coronavirus
|
US20040248804A1
(en)
*
|
2003-05-01 |
2004-12-09 |
Khurshid Iqbal |
Nasal administration of the LH-RH analog Leuprolide
|
US20050123550A1
(en)
*
|
2003-05-12 |
2005-06-09 |
Laurent Philippe E. |
Molecules enhancing dermal delivery of influenza vaccines
|
US7588774B2
(en)
*
|
2003-05-12 |
2009-09-15 |
Becton, Dickinson And Company |
Molecules enhancing dermal delivery of influenza vaccines
|
GB0315632D0
(en)
|
2003-07-04 |
2003-08-13 |
West Pharm Serv Drug Res Ltd |
Pharmaceutical formulations
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
DE602004032481D1
(de)
|
2003-10-02 |
2011-06-09 |
Novartis Vaccines & Diagnostic |
Kombinationsimpfstoffe gegen Meningitis
|
AU2004315509A1
(en)
*
|
2003-12-05 |
2005-08-18 |
Becton, Dickinson And Company |
Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
|
US7968122B2
(en)
*
|
2003-12-10 |
2011-06-28 |
Adventrx Pharmaceuticals, Inc. |
Anti-viral pharmaceutical compositions
|
EP1722815A1
(de)
|
2004-03-09 |
2006-11-22 |
Chiron Corporation |
Influenza-virus-vakzine
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
PT1740217E
(pt)
|
2004-04-30 |
2011-08-02 |
Novartis Ag |
Vacinação meningocócica conjugada
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
JP2007536259A
(ja)
*
|
2004-05-06 |
2007-12-13 |
イヴレア ファーマスーティカルズ インコーポレイテッド |
活性薬剤の送達のための粒子
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
ES2647491T3
(es)
|
2004-05-21 |
2017-12-21 |
Novartis Vaccines And Diagnostics, Inc. |
Vectores del alfavirus para las vacunas del virus de la gripe
|
EP1784211A4
(de)
|
2004-07-29 |
2010-06-30 |
Novartis Vaccines & Diagnostic |
Immunogene zusammensetzungen für grampositive bakterien wie streptococcus agalactiae
|
ES2357747T3
(es)
|
2004-09-09 |
2011-04-29 |
Novartis Vaccines And Diagnostics Gmbh |
Reducción del riesgo iatrogénico asociado con vacunas contra la gripe.
|
WO2006030730A1
(ja)
*
|
2004-09-15 |
2006-03-23 |
Otsuka Pharmaceutical Co., Ltd. |
経粘膜用組成物、及び経粘膜吸収の向上方法
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
JP2008519042A
(ja)
|
2004-11-03 |
2008-06-05 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
インフルエンザワクチン接種
|
US20060121055A1
(en)
*
|
2004-12-06 |
2006-06-08 |
Becton, Dickinson And Company, Inc. |
Compositions with enhanced immunogenicity
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
GB0503337D0
(en)
*
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
NZ599345A
(en)
|
2005-02-18 |
2013-07-26 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic Escherichia Coli
|
US8758764B2
(en)
|
2005-02-18 |
2014-06-24 |
Novartis Vaccines And Diagnostics Srl |
Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
|
US20070059319A1
(en)
*
|
2005-09-15 |
2007-03-15 |
Caliper Life Sciences, Inc. |
Methods of screening for immuno-adjuvants and vaccines comprising anti-microtubule immuno-adjuvants
|
WO2007047749A1
(en)
|
2005-10-18 |
2007-04-26 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
PL1945252T3
(pl)
|
2005-11-04 |
2013-11-29 |
Seqirus Uk Ltd |
Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
|
EP1969001A2
(de)
|
2005-11-22 |
2008-09-17 |
Novartis Vaccines and Diagnostics, Inc. |
Norovirus- und sapovirus-antigene
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
HUE049580T2
(hu)
|
2006-01-27 |
2020-09-28 |
Seqirus Uk Ltd |
Hemagglutinint és mátrixfehérjéket tartalmazó, influenza elleni oltóanyagok
|
CA2643322C
(en)
|
2006-02-24 |
2015-07-21 |
Novartis Ag |
Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
|
EP2010537B1
(de)
|
2006-03-23 |
2011-12-28 |
Novartis AG |
Imidazochinoxalinverbindungen als immunmodulatoren
|
EP2382987A1
(de)
|
2006-03-24 |
2011-11-02 |
Novartis Vaccines and Diagnostics GmbH |
Lagerung von Influenza-Impfstoffen ohne Kühlung
|
EP2382988A1
(de)
|
2006-03-31 |
2011-11-02 |
Novartis AG |
Kombinierte mukosale und parenterale Immunisierung gegen HIV
|
ATE522541T1
(de)
|
2006-06-09 |
2011-09-15 |
Novartis Ag |
Bakterielle adhäsine konformere
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
CA2659552A1
(en)
|
2006-08-16 |
2008-02-21 |
Novartis Ag |
Immunogens from uropathogenic escherichia coli
|
AU2007297178B2
(en)
|
2006-09-11 |
2014-07-24 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
US8652782B2
(en)
|
2006-09-12 |
2014-02-18 |
Longhorn Vaccines & Diagnostics, Llc |
Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
|
US8080645B2
(en)
*
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
JP2011506264A
(ja)
|
2006-12-06 |
2011-03-03 |
ノバルティス アーゲー |
インフルエンザウイルスの4つの株に由来する抗原を含むワクチン
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
EP2112923A1
(de)
|
2007-01-22 |
2009-11-04 |
Targacept Inc. |
Intranasale, orale und sublinguale verabreichung von metanikotin-analogen
|
US20080182819A1
(en)
*
|
2007-01-29 |
2008-07-31 |
Act Iii Licensing, Llc |
Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders
|
PL2185191T3
(pl)
|
2007-06-27 |
2013-02-28 |
Novartis Ag |
Szczepionki przeciwko grypie o małej zawartości dodatków
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
JP5259997B2
(ja)
*
|
2007-07-24 |
2013-08-07 |
大日精化工業株式会社 |
免疫アジュバント分散液
|
JP5297009B2
(ja)
*
|
2007-07-24 |
2013-09-25 |
大日精化工業株式会社 |
免疫アジュバント水溶液
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
US9683256B2
(en)
|
2007-10-01 |
2017-06-20 |
Longhorn Vaccines And Diagnostics, Llc |
Biological specimen collection and transport system
|
US8821885B2
(en)
|
2007-08-27 |
2014-09-02 |
Longhorn Vaccines & Diagnostics, Llc |
Immunogenic compositions and methods
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
RU2471497C2
(ru)
|
2007-09-12 |
2013-01-10 |
Новартис Аг |
Мутантные антигены gas57 и антитела против gas57
|
EP2535428B1
(de)
|
2007-10-01 |
2015-09-09 |
Longhorn Vaccines and Diagnostics, LLC |
System zum Sammeln und Transportieren biologischer Proben sowie Verfahren zu seiner Verwendung
|
US11041216B2
(en)
|
2007-10-01 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
ES2391695T3
(es)
|
2007-12-21 |
2012-11-29 |
Novartis Ag |
Formas mutantes de estreptolisina O
|
ES2532946T3
(es)
|
2008-02-21 |
2015-04-06 |
Novartis Ag |
Polipéptidos PUfH meningocócicos
|
JP2009209086A
(ja)
*
|
2008-03-04 |
2009-09-17 |
Masami Moriyama |
粘膜投与型ワクチン
|
AU2009227674C1
(en)
|
2008-03-18 |
2015-01-29 |
Seqirus UK Limited |
Improvements in preparation of influenza virus vaccine antigens
|
NZ594029A
(en)
|
2009-01-12 |
2014-01-31 |
Novartis Ag |
Cna_b domain antigens in vaccines against gram positive bacteria
|
EP3549602A1
(de)
|
2009-03-06 |
2019-10-09 |
GlaxoSmithKline Biologicals S.A. |
Chlamydia-antigene
|
NZ595689A
(en)
|
2009-04-14 |
2014-03-28 |
Novartis Ag |
Compositions for immunising against staphylococcus aureus
|
SG176532A1
(en)
|
2009-06-15 |
2012-01-30 |
Univ Singapore |
Influenza vaccine, composition, and methods of use
|
KR101342641B1
(ko)
*
|
2009-06-25 |
2013-12-20 |
주식회사 바이오리더스 |
폴리감마글루탐산-키토산 나노입자를 함유하는 면역보강제 조성물
|
WO2011005769A1
(en)
|
2009-07-06 |
2011-01-13 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
CA2803282C
(en)
|
2009-07-06 |
2018-05-01 |
David E. Anderson |
Methods for preparing vesicles and formulations produced therefrom
|
WO2011004263A2
(en)
|
2009-07-07 |
2011-01-13 |
Novartis Ag |
Conserved escherichia coli immunogens
|
LT3178490T
(lt)
|
2009-07-15 |
2022-07-25 |
Glaxosmithkline Biologicals S.A. |
Rsv f baltymų kompozicijos ir jų gamybos būdai
|
WO2011007257A1
(en)
|
2009-07-16 |
2011-01-20 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
CN102596240B
(zh)
|
2009-08-27 |
2015-02-04 |
诺华股份有限公司 |
包括脑膜炎球菌fHBP序列的杂交多肽
|
JP2011057605A
(ja)
*
|
2009-09-09 |
2011-03-24 |
Masami Moriyama |
粘膜投与型ワクチン
|
SG178904A1
(en)
|
2009-09-10 |
2012-04-27 |
Novartis Ag |
Combination vaccines against respiratory tract diseases
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
BR112012009014B8
(pt)
|
2009-09-30 |
2022-10-04 |
Novartis Ag |
Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
|
CA2776004A1
(en)
|
2009-09-30 |
2011-04-07 |
Novartis Ag |
Expression of meningococcal fhbp polypeptides
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
US20130022633A1
(en)
|
2009-10-27 |
2013-01-24 |
University Of Florence |
MENINGOCOCCAL fHBP POLYPEPTIDES
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
WO2011080595A2
(en)
|
2009-12-30 |
2011-07-07 |
Novartis Ag |
Polysaccharide immunogens conjugated to e. coli carrier proteins
|
WO2011101465A1
(en)
|
2010-02-19 |
2011-08-25 |
Intercell Ag |
Ic31 nanoparticles
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
EP2556151A1
(de)
|
2010-04-07 |
2013-02-13 |
Novartis AG |
Verfahren zur erzeugung von virusähnlichen parvovirus-b19-partikeln
|
EP2558069A1
(de)
|
2010-04-13 |
2013-02-20 |
Novartis AG |
Benzonapthyridinzusammensetzungen und ihre verwendung
|
RU2465006C2
(ru)
*
|
2010-04-14 |
2012-10-27 |
Учреждение Российской академии медицинских наук научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова РАМН (НИИВС им. И.И. Мечникова РАМН) |
Способ повышения иммуногенности холодоадаптированной живой гриппозной вакцины
|
WO2011149564A1
(en)
|
2010-05-28 |
2011-12-01 |
Tetris Online, Inc. |
Interactive hybrid asynchronous computer game infrastructure
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
AU2011276328C1
(en)
|
2010-07-06 |
2016-01-21 |
Novartis Ag |
Norovirus derived immunogenic compositions and methods
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
US9610248B2
(en)
|
2010-07-06 |
2017-04-04 |
Variation Biotechnologies, Inc. |
Compositions and methods for treating influenza
|
EP2614163B1
(de)
|
2010-09-07 |
2016-01-06 |
Novartis AG |
Generische tests für den nachweis von säuger-reoviridae
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
EP2655389A2
(de)
|
2010-12-24 |
2013-10-30 |
Novartis AG |
Verbindungen
|
CA2862864C
(en)
|
2011-01-13 |
2018-12-11 |
Variation Biotechnologies Inc. |
Compositions and methods for treating viral infections
|
AU2012205315B2
(en)
|
2011-01-13 |
2017-05-04 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
EP4144368A1
(de)
|
2011-01-26 |
2023-03-08 |
GlaxoSmithKline Biologicals S.A. |
Rsv-immunisierungstherapie
|
HUE048777T2
(hu)
|
2011-05-13 |
2020-08-28 |
Glaxosmithkline Biologicals Sa |
Pre-fúziós RSV F antigének
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
WO2013006842A2
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
CN103764171B
(zh)
|
2011-07-08 |
2016-08-17 |
诺华股份有限公司 |
酪氨酸连接方法
|
WO2013016460A1
(en)
|
2011-07-25 |
2013-01-31 |
Novartis Ag |
Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
TR201909110T4
(tr)
|
2011-09-14 |
2019-07-22 |
Glaxosmithkline Biologicals Sa |
Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler.
|
US9511130B2
(en)
|
2011-09-14 |
2016-12-06 |
Glaxosmithkline Biologicals Sa |
Escherichia coli vaccine combination
|
AU2012335208B2
(en)
|
2011-11-07 |
2017-08-31 |
Glaxosmithkline Biologicals S.A. |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
US20140328876A1
(en)
|
2011-11-18 |
2014-11-06 |
Variation Biotechnologies Inc. |
Synthetic derivatives of mpl and uses thereof
|
JP6084631B2
(ja)
|
2011-12-08 |
2017-02-22 |
ノバルティス アーゲー |
Clostridiumdifficile毒素ベースのワクチン
|
AU2013208693B2
(en)
|
2012-01-12 |
2017-12-07 |
Variation Biotechnologies Inc. |
Compositions and methods for treating viral infections
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
CA3207612A1
(en)
|
2012-01-26 |
2013-08-01 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
US20150079077A1
(en)
|
2012-01-27 |
2015-03-19 |
Variation Biotechnologies, Inc. |
Methods and compositions for therapeutic agents
|
RU2014138418A
(ru)
|
2012-02-24 |
2016-04-10 |
Новартис Аг |
Белки пилей и композиции
|
CA2871520C
(en)
|
2012-04-26 |
2020-12-29 |
Novartis Ag |
Antigens from non-typeable h. influenzae
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
WO2013174832A1
(en)
|
2012-05-22 |
2013-11-28 |
Novartis Ag |
Meningococcus serogroup x conjugate
|
EP2869842A1
(de)
|
2012-07-06 |
2015-05-13 |
Novartis AG |
Immunogene zusammensetzungen und verwendungen davon
|
US20150224181A1
(en)
|
2012-09-14 |
2015-08-13 |
The United States Of America As Represented By The Secretary Department Of Health And Human Se |
Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
|
AU2013320313B2
(en)
|
2012-09-18 |
2018-07-12 |
Glaxosmithkline Biologicals Sa |
Outer membrane vesicles
|
SG11201502197XA
(en)
|
2012-10-02 |
2015-04-29 |
Glaxosmithkline Biolog Sa |
Nonlinear saccharide conjugates
|
MX2015002482A
(es)
|
2012-10-03 |
2016-01-08 |
Glaxosmithkline Biolog Sa |
Composicion inmunogenica.
|
SG11201503319UA
(en)
*
|
2012-10-29 |
2015-05-28 |
Univ Arkansas |
Novel mucosal adjuvants and delivery systems
|
CN105142666A
(zh)
|
2012-11-30 |
2015-12-09 |
葛兰素史密丝克莱恩生物有限公司 |
假单胞菌抗原和抗原组合
|
EP2870974A1
(de)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella-Konjugatimpfstoffe
|
EP3294448A4
(de)
|
2015-05-14 |
2018-12-12 |
Longhorn Vaccines and Diagnostics, LLC |
Schnellverfahren zur extraktion von nukleinsäuren aus biologischen proben
|
EP4333868A1
(de)
|
2021-05-04 |
2024-03-13 |
King Abdullah University Of Science And Technology |
Immunogene zusammensetzungen von mutiertem sars-cov-2 n-protein und gen und verfahren zur verwendung davon
|
WO2023079528A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
|
WO2023079529A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Re-focusing protein booster immunization compositions and methods of use thereof
|